局部他克莫司溶液治疗自身免疫性多内分泌腺综合征1型相关角膜炎
回顾性综述纳入10例自身免疫性多内分泌腺综合征1型患者,接受0.01%他克莫司滴眼液治疗,平均疗程26个月。治疗后10例中7例畏光改善,但所有患者角膜炎严重程度均无临床可检测的改善,平均最佳矫正视力治疗前后均为0.1。结论认为局部他克莫司可有效减轻畏光,但对角膜炎严重程度无影响。
要点
- 10例APS-1相关角膜炎患者使用0.01%他克莫司滴眼液,平均疗程26个月。
- 治疗后10例中7例畏光改善,3例畏光持续。
- 所有患者角膜炎严重程度无临床可检测的改善,平均最佳矫正视力治疗前后均为0.1。
核心结论
- 局部他克莫司可有效减轻APS-1相关角膜炎患者的畏光,但对角膜炎严重程度无影响。
研究设计与样本
- 回顾性综述,纳入10例自身免疫性多内分泌腺综合征1型患者,2012年3月1日至2016年4月30日期间在The Eye Center接受0.01%他克莫司滴眼液治疗。
主要发现
- 10例患者中男性5例、女性5例,平均年龄11岁,年龄范围3-42岁。
- 局部他克莫司平均治疗时长26个月,范围8-46个月。
- 治疗后10例中7例畏光改善,3例畏光持续。
- 所有患者角膜炎严重程度均无临床可检测的改善。
- 平均最佳矫正视力治疗前和治疗后均为0.1。
临床怎么用
- 原文结论认为局部他克莫司可有效减轻APS-1相关角膜炎患者的畏光,但对角膜炎严重程度无影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the efficacy of topical tacrloimus eye drops in the treatment of keratitis associated with autoimmune polyglandular syndrome (APS)-1. METHODS: This is a retrospective review of 10 patients with APS-1. The patients were treated with topical tacrolimus 0.01% solution at The Eye Center, between 1 March 2012 and 30 April 2016. The outcome measures included improvement in visual acuity, photophobia and keratitis following treatment. Clinical assessment was carried out before, during and on the last visit following initiation of therapy. RESULTS: A total of 10 patients were included. There were five male and five female patients. The mean age was 11 years with age range of 3-42 years. The mean duration of treatment with topical tacrolimus was 26 months (range 8-46 months). There was improvement of photophobia in 7 out of 10 patients following therapy with topical tacrolimus. In three patients, the photophobia was persistent. There was no clinically detectable improvement in the severity of keratitis in all patients. The mean best corrected visual acuity was 0.1 before and following therapy. CONCLUSION: Topical tacrolimus is effective in reducing the photophobia in patients with APS-1-associated keratitis, but showed no effects on the severity of keratitis.
引用
- Shoughy SS, Tabbara KF. Topical tacrolimus solution in autoimmune polyglandular syndrome-1-associated keratitis. Br J Ophthalmol. 2017. PMID: 28137823. doi:10.1136/bjophthalmol-2016-309808
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。